




FEB D 2 2001

TECH CENTER 1600/2900



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

In re Application of:

Group Art Unit: 1636

JAN 25 2001

Elisabetta Vegeto et al.

Examiner: W. Sandals

TECH CENTER 1600/2900

Serial No. 09/465,133

Filed: December 16, 1999

For: MUTATED STEROID HORMONE RECEPTORS, METHODS FOR THEIR USE AND MOLECULAR SWITCH FOR GENE

THERAPY



TRANSMITTAL

BOX SEQUENCE Commissioner for Patents Washington, D.C. 20231

Sir:

Applicants submit the following documents with this Transmittal Letter.

- (1) Amendment and Response;
- (2) Copy of the Notice to Comply with Requirements for Patent Applications
 Containing Nucleotide Sequence and Amino Acid Sequence Disclosures;
- (3) Amended Drawing (Fig. 2B) with amendments marked in red ink;
- (4) Nucleotide and Amino Acid sequence listing information (paper format);

CERTIFICATE OF MAILING (37 C.F.R. §1.8a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Name of Person Mailing

Signature of Person Mailing Paper

Date of Deposit

- (5) Nucleotide and Amino Acid sequence listing information (computer format); and
- (6) Return Postcard.

LYON & LYON LLP

Dated: January 18, 2001

Michael J. Wise

Reg. No. 34,047

22240

22249
PATENT TRADEMARK OFFICE

LYON & LYON LLP

Suite 4700

633 W. Fifth Street

Los Angeles, CA 90071

Tel: (213) 489-1600

Fax: (213) 955-0440

APPLICATION NO.

T-201 P.005/005 F-457

OTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING UCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

me nucleotide and/or amino acid sequence disclosure contained in this application does ot comply with the requirements for such a disclosure as s t forth in 37 CFR 1.821 -.825 for the following reason(s):

This application clearly fails to comply with the requirements or 37 CFR 1.821 Applicant's attention is directed to these regulations, published at 1114 OG 29, ly 15, 1990 and at 55 FR 18230, May 1, 1990. This application does not contain, as a separate part of the disclosure on per copy, a "Sequence Listing" as required by 37 CPR 1.821(c). A copy of the "Sequence Listing" in computer readable form has not been ibmitted as required by 37 CFR 1.821(e). A copy of the "Sequence Listing" in computer readable form has been submitted. wever; the content of the computer readable form does not comply with the requirements 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw "quence Listing." The computer readable form that has been filed with this application has been und to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem port. A substitute computer readable form must be submitted as required by 37 CFR 825(d). The paper copy of the "Sequence Listing" is not the same as the computer adable form of the "Sequence Listing" as required by 37 CFR 1.821(e). gue 3 withent plicant must provide: An initial or substitute computer readable form (CRF) copy of the "Sequence

sting"

An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification

A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or $\overline{1.821(g)}$ or 1.825(b) or 1.825(d)

r questions regarding compliance with these requirements, please contact:

r Rules Interpretation, call (703) 308-1123

r CRF submission help, call (703) 308-4212 r PatentIn software help, call (703) 557-0400 RECEIVED

FEB 0 2 2001

r turn a copy of this notic with your r spons . Pl as

TECH CENTER 1600/2900